Abatacept - Bristol-Myers Squibb

Drug Profile

Abatacept - Bristol-Myers Squibb

Alternative Names: BMS-188667; BMS-188667SC; CTLA4-Ig; hCTLA4-Ig-Bristol-Myers-Squibb; ONO-4164; ONO-4164-IV; ONO-4164-SC; Orencia; Orencia IV; Orencia SC

Latest Information Update: 15 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bristol-Myers Squibb
  • Developer Bristol-Myers Squibb; National Institute of Allergy and Infectious Diseases; Ono Pharmaceutical; Simcere Pharmaceutical Group; University Medical Center Groningen; University of Michigan; University of Pittsburgh
  • Class Antipsoriatics; Antirheumatics; Eye disorder therapies; Immunoconjugates; Immunoglobulin fusion proteins
  • Mechanism of Action T cell activation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis
  • Phase III Lupus nephritis; Myositis; Sjogren's syndrome
  • Phase II Diffuse scleroderma; Interstitial lung diseases; Nephrotic syndrome
  • Preclinical Inflammation
  • No development reported Ulcerative colitis
  • Discontinued Crohn's disease; Graft-versus-host disease; Multiple sclerosis; Psoriasis; Systemic lupus erythematosus; Transplant rejection; Xenotransplant rejection

Most Recent Events

  • 09 Oct 2017 Phase-II clinical trials in Interstitial lung diseases in USA (SC)
  • 09 Oct 2017 Bristol-Myers Squibb in collaboration with University of Pittsburgh initiates a phase-II clinical trial for Interstitial lung diseases in USA (SC) (NCT03215927)
  • 07 Aug 2017 Phase-III clinical trials in Myositis in Czech Republic, Denmark, Sweden (SC) (EudraCT2016-002269-77)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top